Celldex Therapeutics, Inc. (FRA:TCE2)

Market Cap	1.75B +42.3%
Revenue (ttm)	1.32M -78.0%
Net Income	-220.38M
EPS	-3.32
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	230
Average Volume	15
Open	27.40
Previous Close	27.20
Day's Range	27.40 - 27.40
52-Week Range	13.20 - 27.40
Beta	n/a
RSI	64.92
Earnings Date	May 4, 2026

About Celldex Therapeutics

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias,...

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Anthony Marucci
• Employees: 198
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: TCE2

Financial Performance

In 2025, Celldex Therapeutics's revenue was $1.55 million, a decrease of -77.99% compared to the previous year's $7.02 million. Losses were -$258.76 million, 63.9% more than in 2024.

Financial numbers in USD